CareDx, Inc (NASDAQ: CDNA) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $3.9B. The Maz Rating grades it against the other companies in its sector.
CareDx, Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $74.56, CareDx, Inc trades at 29.5x trailing earnings, 7.8x sales and 8.2x book value, with an EV/EBITDA of 129.0. Over the last twelve months it generated about $504M of revenue and $133M of net income. It runs a gross margin of 71.0%, an operating margin of 0.8% and a net margin of 25.9%. It shows return on equity of 34.1%, return on invested capital of 0.8% and a free cash flow yield of 1.5%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 2.31. Over the past 52 weeks the share price ranged from $15.22 to $90.87, with a beta of 2.49.
CareDx, Inc does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 11 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, CareDx, Inc (CDNA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.71% / 30% · Interest income / Revenue 1.58% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.71% / 33% · Receivables / Mkt Cap (36m) 1.47% / 49% · Interest income / Revenue 1.58% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.71% / 33.33% · Receivables / Mkt Cap (24m) 1.47% / 33.33% · Interest income / Revenue 1.58% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 49.5% / 33.33% · Receivables / Avg Assets (4Q) 8.47% / 33.33% · Interest income / Revenue 1.58% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 39.0% / 33.33% · (Cash+Recv) / Total Assets 46.5% / 33.33% · Interest income / Revenue 1.58% / 5% | Fail |
It depends on the standard you follow. As of September 2026, CareDx, Inc (CDNA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. CareDx, Inc is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.58% of each dividend: CareDx, Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.